Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 102, Issue 3, Pages 571-579Publisher
WILEY
DOI: 10.1002/jcb.21491
Keywords
prostate cancer; prostate specific membrane antigen (PSMA); prostate specific antigen (PSA)
Categories
Ask authors/readers for more resources
Over a half century ago, Charles Huggins demonstrated the response of prostate cancer to androgen deprivation therapy. Subsequently, many discoveries and evolving findings continued to support a research rationale focused on the androgen receptor (AR) as a key target for prostate cancer. More recently, preliminary trials have suggested that other targets could also be useful in the treatment of prostate cancer, and the proposed strategies for treatment have ranged from targeted toxins to immunotherapeutic agents. We provide an overview of some of these approaches, with an emphasis on those that employ prostate specific membrane antigen (PSMA) as a target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available